SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?


To: Dr Goodhybe who wrote (1043)10/29/1999 6:27:00 PM
From: jerryriti  Read Replies (1) | Respond to of 1728
 
Robertson Stephens Upgrades AFFX to a Strong Buy
Rating

SAN FRANCISCO--(BUSINESS WIRE)--Oct. 29, 1999--Robertson Stephens Senior
Biotechnology Analyst Michael G. King Jr. today upgraded Affymetrix (NASDAQ:AFFX -
news) to a Strong Buy rating from a Buy. Affymetrix is one of the world's leading genomics
companies and the developer of the GeneChip© genetic microarray system.

``We are upgrading Affymetrix to a Strong Buy rating from a Buy,' said King. ``Shares of Affymetrix have been weak over the
last several days, in our opinion, due to a variety of specious concerns, including competition, patents and insider selling. While
each of these concerns has a basis in legitimate sources, the degree to which they have been extrapolated in unjustified, in our
view. We are more than comfortable with the company's position on each of these fronts.'

``We maintain that Affymetrix' market-dominant position is secure based on several reasons, including its strong intellectual
property portfolio, broad-product offering and numerous-customer relationships,' said King. ``We continue to view Affymetrix
as one of the most exciting `hardware' plays in the biotech industry due to its critical involvement in the genomics revolution.
Fundamentally, the company is in the best shape it has ever been, and we expect fundamentals to improve going forward.'

``We believe the recent-price weakness has created an outstanding buying opportunity, and we are reiterating our 12-month
price target of $138 per share,' said King.

Clients interested in receiving more information should contact their salesperson at (415) 781-9700.

BancBoston Robertson Stephens Inc. (``Robertson Stephens') is the leading full-service investment bank focused exclusively
on growth companies. To date in 1999, the firm has completed over 130 public offerings and over 30 private offerings, raising
more than $26 billion in capital for clients. The firm's 47 research analysts cover nearly 700 companies. Founded in 1978,
Robertson Stephens is a section 20 subsidiary of Fleet Boston Corporation (NYSE: FLT - news) and a member of the NASD
and all major exchanges. Together, Robertson Stephens, BancBoston Robertson Stephens International Ltd., and Robertson
Stephens Evergreen Securities Ltd. employ over 1,000 employees worldwide with offices in Boston, San Francisco, New
York, Menlo Park, Chicago, London, and Tel Aviv. For more information about the firm, please visit our Web site at
www.rsco.com.

The foregoing synopses are qualified in their entirety by the more detailed information contained in the full research reports,
including the discussion of certain risks associated with an investment in the above-mentioned securities contained in
``Investment Risks.'

The information contained herein is not a complete analysis of every material fact respecting any company, industry or security.
Although opinions and estimates expressed herein reflect the current judgment of BancBoston Robertson Stephens Inc., the
information upon which such opinions and estimates are based is not necessarily updated on a regular basis; when it is, the date
of the change in estimate will be noted. In addition, opinions and estimates are subject to change without notice. This Report
contains forward-looking statements, which involve risks and uncertainties. Actual results may differ significantly from the results
described in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those
discussed in ``Investment Risks.' BancBoston Robertson Stephens Inc. from time to time performs corporate finance or other
services for some companies described herein and may occasionally possess material, nonpublic information regarding such
companies. This information is not used in the preparation of the opinions and estimates herein. While the information contained
in this Report and the opinions contained herein are based on sources believed to be reliable, BancBoston Robertson Stephens
Inc. has not independently verified the facts, assumptions and estimates contained in this Report. Accordingly, no representation
or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or
correctness of the information and opinions contained in this Report. BancBoston Robertson Stephens Inc., its managing
directors, its affiliates, and/or its employees may have an interest in the securities of the issue(s) described and may make
purchases or sales while this report is in circulation. BancBoston Robertson Stephens International Ltd. is regulated by the
Securities and Futures Authority in the United Kingdom. This publication is not meant for private customers. The securities
discussed herein are not FDIC insured, are not deposits or other obligations or guarantees of Fleet Bank or BankBoston N.A.,
and are subject to investment risk, including possible loss of any principal amount invested.